ULK1-IN-4(compound 12i)是一种 ULK1 抑制剂,对人源 ULK1 的 IC50 为 4.7 μM,并对 Aurora A/Aurora B 激酶具有选择性,其通过与 ULK1 的 Cys182 残基巯基形成共价键来抑制 ULK1 激酶活性,同时可抑制结直肠癌细胞生长,并在结直肠癌小鼠模型中表现出肿瘤抑制活性。
ULK1-IN-4
产品编号: MS-Y26360 分子式: C29H29ClN4O4 分子量: 533.02
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

ULK1-IN-4(compound 12i)是一种 ULK1 抑制剂,对人源 ULK1 的 IC50 为 4.7 μM,并对 Aurora A/Aurora B 激酶具有选择性,其通过与 ULK1 的 Cys182 残基巯基形成共价键来抑制 ULK1 激酶活性,同时可抑制结直肠癌细胞生长,并在结直肠癌小鼠模型中表现出肿瘤抑制活性。

生物实验数据

生物活性 ULK1-IN-4 (compound 12i) is a ULK1 inhibitor with an IC50 of 4.7 μM against human ULK1 and selectivity over Aurora A/Aurora B kinases that inhibits ULK1 kinase activity by forming a covalent bond with the thiol group of the Cys182 residue of ULK1, suppresses the growth of colorectal cancer cells, and exhibits tumor-suppressive activity in a mouse model of colorectal cancer.
体外研究
(In Vitro)

ULK1-IN-4 (compound 12i) (2.5-10 μM; 48 h) 可在处理 48 h 后激活 SW620、HCT116 和 CT26 结直肠癌细胞 (CRC 细胞) 的凋亡通路,这一点可通过凋亡相关蛋白的表达变化得到证实。
ULK1-IN-4 (10 μM; 24 h) 可在基础自噬和雷帕霉素诱导的自噬条件下,抑制 HCT116 结直肠癌细胞经 24 h 处理后的早期自噬流。
ULK1-IN-4 (10-20 μM; 48 h) 以剂量依赖的方式在处理 48 h 后诱导 SW620、HCT116 和 CT26 结直肠癌 (CRC) 细胞发生凋亡。
ULK1-IN-4 (5-10 μM; 24-48 h) 以剂量依赖的方式抑制 SW620、HCT116 和 CT26 结直肠癌细胞 (CRC 细胞) 的迁移能力,处理时间为 24 h 和 48 h。
ULK1-IN-4 (5-10 μM; 24 h) 可在处理 24 h 后抑制 SW620、HCT116 和 CT26 结直肠癌 (CRC) 细胞的迁移能力,并上调 E-cadherin 的表达。
ULK1-IN-4 (10 μM; 48 h) 可发挥多种药理学作用,包括细胞周期阻滞、迁移抑制、自噬抑制和凋亡诱导,这些作用在 SW620 结直肠癌细胞中依赖于对 ULK1 的靶向作用。

Cell Proliferation Assay

Cell Line: Human colorectal cancer cell lines SW620, HCT116; mouse colorectal cancer cell line CT26
Concentration: Gradient concentrations used to determine IC50
Incubation Time: 48 h
Result: Inhibited proliferation of SW620 cells with an IC50 of 13.31 μM.
Inhibited proliferation of HCT116 cells with an IC50 of 9.76 μM.
Inhibited proliferation of CT26 cells with an IC50 of 13.07 μM.

Cell Proliferation Assay

Cell Line: Human colorectal cancer cell lines SW620, HCT116; mouse colorectal cancer cell line CT26
Concentration: 5-10 μM
Incubation Time: 2 weeks (continuous treatment)
Result: Dose-dependently reduced both the number and size of colonies in SW620, HCT116, and CT26 cells.

Cell Cycle Analysis

Cell Line: Human colorectal cancer cell lines SW620, HCT116; mouse colorectal cancer cell line CT26
Concentration: 10-20 μM
Incubation Time: 48 h
Result: Induced cell cycle arrest at the S or G2/M phase in all three cell lines: in SW620 cells, 10 μM caused G1:63.2%, S:19.27%, G2/M:16.96%; 20 μM caused G1:58.9%, S:23.3%, G2/M:17.5%.
In HCT116 cells, 10 μM caused G1:88.65%, S:11.38%, G2/M:9.22%; 20 μM caused G1:88.61%, S:16.88%, G2/M:14.12%.
In CT26 cells, 10 μM caused G1:59.27%, S:24.35%, G2/M:16.25%; 20 μM caused G1:55.48%, S:24.34%, G2/M:19.55%.

Western Blot Analysis

Cell Line: Human colorectal cancer cell lines SW620, HCT116; mouse colorectal cancer cell line CT26
Concentration: 2.5-10 μM
Incubation Time: 48 h
Result: Dose-dependently increased levels of the autophagy substrate p62.
Reduced conversion of LC3 I to LC3 II.
Decreased levels of Beclin1 and phospho-Beclin-1 (Ser15) in all three cell lines.\nDose-dependently upregulated expression levels of cleaved-caspase-3 and cleaved-PARP.
Increased levels of the pro-apoptotic protein Bax.
Downregulated levels of the anti-apoptotic protein Bcl2 in all three cell lines.

Apoptosis Analysis

Cell Line: Human colorectal cancer cell lines SW620, HCT116; mouse colorectal cancer cell line CT26
Concentration: 10-20 μM
Incubation Time: 48 h
Result: Dose-dependently increased the proportion of apoptotic cells (early + late) in all three cell lines: in SW620 cells, 10 μM caused 26.01% apoptosis, 20 μM caused 63.79% apoptosis; in HCT116 cells, 10 μM caused 19.52% apoptosis, 20 μM caused 45.18% apoptosis; in CT26 cells, 10 μM caused 12.81% apoptosis, 20 μM caused 100.68% apoptosis.

Cell Migration Assay

Cell Line: Human colorectal cancer cell lines SW620, HCT116; mouse colorectal cancer cell line CT26
Concentration: 5-10 μM
Incubation Time: 24 h; 48 h
Result: Dose-dependently suppressed wound closure in all three cell lines after 24 and 48 h of treatment.

Cell Migration Assay

Cell Line: Human colorectal cancer cell lines SW620, HCT116; mouse colorectal cancer cell line CT26
Concentration: 5-10 μM
Incubation Time: 24 h
Result: Dose-dependently reduced the number of migrated cells in all three cell lines.
Upregulated levels of E-cadherin.
体内研究
(In Vivo)

ULK1-IN-4 (20-40 mg/kg; i.p.; 每 2 天 1 次; 14 d) 可在体内以剂量依赖方式抑制 Balb/c 小鼠的结直肠肿瘤生长,在 40 mg/kg 剂量下的肿瘤生长抑制率达 70.4%,且未观察到全身毒性。

Animal Model: Balb/c (6-7-week-old female, subcutaneously injected with 1×106 CT26 cells)
Dosage: 20 mg/kg; 40 mg/kg
Administration: i.p.; once every two days; 14 days
Result: Achieved a tumor growth inhibition (TGI) rate of 19.2% and an average tumor weight of 0.873 g at 20 mg/kg.
Achieved a TGI rate of 70.4% and an average tumor weight of 0.327 g at 40 mg/kg.
Caused no significant body weight loss or abnormal behaviors during treatment.
Showed no significant histopathological changes in heart, liver, spleen, lungs, and kidneys compared to controls.
Downregulated ULK1, p-Beclin-1 (Ser15), and Beclin-1 expression, upregulated p62 expression, increased TUNEL-positive apoptotic cells, elevated cleaved-caspase 3 levels, and reduced Ki67-positive proliferative cells at 40 mg/kg.

化学信息

分子量 533.02
分子式 C29H29ClN4O4

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础